Alpha 2-adrenergic sensitivity in Parkinson's disease.

Clin Neuropharmacol

Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 317, CHU, Faculté de Médecine, Toulouse, France.

Published: April 1989

Download full-text PDF

Source
http://dx.doi.org/10.1097/00002826-198904000-00010DOI Listing

Publication Analysis

Top Keywords

alpha 2-adrenergic
4
2-adrenergic sensitivity
4
sensitivity parkinson's
4
parkinson's disease
4
alpha
1
sensitivity
1
parkinson's
1
disease
1

Similar Publications

NHERF2 regulatory function in signal transduction pathways and control of gene expression: Implications for cellular homeostasis and breast cancer.

Arch Med Res

January 2025

Programa de Investigación de Cancer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico; Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address:

Na⁺/H⁺ exchanger regulatory factor 2 (NHERF2) is a nucleocytoplasmic protein initially identified as a regulator of membrane-bound sodium-hydrogen exchanger 3 (NHE3). In the cytoplasm, NHERF2 regulates the activity of G protein-coupled receptors (GPCRs), including beta-2 adrenergic receptor (2β-AR), lysophosphatidic acid receptor 2, and parathyroid hormone type 1 receptor. In the nucleus, NHERF2 acts as a coregulator of transcription factors such as sex-determining region Y protein (SRY), involved in male sex determination, and estrogen receptor alpha (ERα).

View Article and Find Full Text PDF

Management of alcohol withdrawal syndromes in general hospital settings.

BMJ

January 2025

Division of Addiction Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

The covid-19 pandemic was associated with an unprecedented increase in alcohol consumption and associated morbidity, including hospitalizations for alcohol withdrawal. Clinicians based in hospitals must be ready to identify, assess, risk-stratify, and treat alcohol withdrawal with evidence based interventions. In this clinically focused review, we outline the epidemiology, pathophysiology, clinical manifestations, screening, assessment, and treatment of alcohol withdrawal in the general hospital population.

View Article and Find Full Text PDF

Background: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings.

View Article and Find Full Text PDF

Antinociceptive Potential of L. Bark Extract and Caffeic Acid: Insights into Pain Modulation Pathways.

Pharmaceuticals (Basel)

December 2024

Laboratory of Pharmacology and Molecular Chemistry, Department of Chemical Biology, Regional University of Cariri (URCA), Rua Coronel Antônio Luis 1161, Pimenta, Crato 63105-000, Ceará, Brazil.

This study evaluated the antinociceptive effect of the L. bark extract (HEXA) and its primary component, caffeic acid (CA), through in vivo assays. : The antinociceptive properties were assessed using abdominal writhing, hot plate, and Von Frey tests.

View Article and Find Full Text PDF

Dexmedetomidine (DEX) is a selective alpha-2 adrenergic receptor agonist with sedative and anxiolytic properties. Increasing evidence reports that DEX has a neuroprotective effect. In this study, we investigated the potential effects of DEX on learning and memory functions in rats with experimental cognitive impairment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!